12/5
08:42 am
anvs
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace [Yahoo! Finance]
Medium
Report
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace [Yahoo! Finance]
12/5
08:30 am
anvs
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
Medium
Report
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace
12/4
08:42 am
anvs
/C O R R E C T I O N -- Today's Marketplace/
Medium
Report
/C O R R E C T I O N -- Today's Marketplace/
11/25
08:10 am
anvs
Annovis to Host Year-End Investor Webcast on December 11, 2024 [Yahoo! Finance]
Low
Report
Annovis to Host Year-End Investor Webcast on December 11, 2024 [Yahoo! Finance]
11/25
08:00 am
anvs
Annovis to Host Year-End Investor Webcast on December 11, 2024
Low
Report
Annovis to Host Year-End Investor Webcast on December 11, 2024
11/12
08:00 am
anvs
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
Medium
Report
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
11/11
08:09 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/11
08:00 am
anvs
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
High
Report
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
11/7
08:00 am
anvs
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
Low
Report
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
10/31
08:00 am
anvs
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
Low
Report
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
10/25
08:11 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock.
Medium
Report
Annovis Bio, Inc. (NYSE: ANVS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $25.00 price target on the stock.
10/22
08:11 am
anvs
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 [Financial Post (Toronto, Ontario, Canada)]
10/22
08:00 am
anvs
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Low
Report
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
10/17
11:03 pm
anvs
Annovis Bio To Continue Alzheimer's Disease Clinical Trials [Seeking Alpha]
High
Report
Annovis Bio To Continue Alzheimer's Disease Clinical Trials [Seeking Alpha]
10/16
08:31 am
anvs
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/15
02:45 pm
anvs
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's [Seeking Alpha]
Low
Report
Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's [Seeking Alpha]
10/15
08:06 am
anvs
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs [Financial Post (Toronto, Ontario, Canada)]
10/15
08:00 am
anvs
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
Medium
Report
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
10/3
08:39 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases [Financial Post (Toronto, Ontario, Canada)]
10/3
08:30 am
anvs
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Low
Report
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
10/3
08:30 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
Low
Report
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
10/2
08:34 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations [Financial Post (Toronto, Ontario, Canada)]
10/2
08:30 am
anvs
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Medium
Report
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
10/1
08:30 am
anvs
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
Low
Report
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
10/1
08:30 am
anvs
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
Low
Report
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition